TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Clinical Signs of Catheter Related Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Weekly number of exemptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia-Subjective Survey Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysphagia-Objective Functional Outcome Swallowing Score (FOSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MET expression in colorectal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasminogen Activator Inhibitor -1 expression in colorectal cancer tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COX-2 expression in colorectal cancer tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline 6 Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in serum VEGF concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum solifenacin succinate pharmacokinetics parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial objective response rate (iORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Major adverse event rate (MAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Target lesion primary patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum tolerated dose of HG146
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of severe oral mucositis (grade 3-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of individual lesions response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary antitumor activity of SB 11285
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Scale for Suicide Ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adipokine DNA polymorphism correlations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased Overall Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of women experiencing specific safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Fold Rise (GMFR) From Day 1 in Varicella Zoster Virus (VZV) Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer (GMT) of VZV Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Clinical Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pharmacokinetic parameters of Boceprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported frequency of distributive sharing of drug equipment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: number of adverse events of vaccination therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response According to RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety of infusion of autologous mesothelin specific CAR T cells
Endpoint domain: Adverse events/effects
Primary endpoint: post-prandial insulin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Degree and number of adverse events reported
Endpoint domain: Adverse events/effects
Primary endpoint: tolerance-related biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Event Profile
Endpoint domain: Adverse events/effects
Primary endpoint: Platelet yield estimate accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in diagnostic eating disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in global eating disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in intuitive eating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AUC of survival prediction performance
Endpoint domain: Mortality/survival
Primary endpoint: Surgical morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hospital Readmission Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Faecal incontinence severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cystoid macular edema (CME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Number of Study Participants With Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life indices - Roland Morris Disability Questionnaire (RMDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient-Reported Outcomes Measurement Information System (PROMIS Global-10)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean % difference in pruritus visual analog score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life, EQ-5D-3L-index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EQ- visual analogue scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mortality at ICU discharge
Endpoint domain: Mortality/survival
Primary endpoint: Cocaine abstinence as assessed by urinalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine abstinence as assessed by self-reports
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stiffness obtained from myotonometric assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elasticity obtained from myotonometric assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final volume of cerebral infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Dysphonia Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Acoustic Voice Quality Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pediatric Voice Handicap Index (pVHI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Overall Severity From Consensus Auditory-Perceptual Evaluation of Voice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Constant-Murley Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subject incidence of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate in each taxane-resistant tumor type
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: total clearance of paracetamol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: metabolite specific clearance estimates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily physical activity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognition composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioural Symptoms Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attention and processing speed (full scale IQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in cardiac rehabilitation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Spontaneous Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores on visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Number of Monthly Vertigo Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With JE Seroprotection Before and Following a Dose of Live Attenuated JE-CV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With JE Seroconversion Following a Dose of Live Attenuated JE-CV Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Solicited Injection-Site Reactions and Systemic Reactions Following a Dose of Live Attenuated JE-CV or Varicella Vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Premature Infant Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neonatal Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic sensitivity of biomarker panel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of visualization of the small bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Characterization of degenerated intervertebral disc cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improved GCS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Return of cerebral or brainstem functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean frequency of communication strategy use
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Quality of Life Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reticulation Ratio from Computerized Tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall survival of all randomized patients
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival of patients scored as IPSS-R very high risk
Endpoint domain: Mortality/survival
Primary endpoint: Pain Level Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Confirmed Objective Response (OR) as Per RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Confirmed Objective Response (OR) as Per RECIST v1.1 and PCWG3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: screening success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Who Eradicated Methane on Breath Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall score given by the patient to the knee replacement process
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Ultrasonography incidence of deep vein thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Oxford Knee Score pre op and post op
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the number of inflammatory lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percent of patients who achieve success for the acne global severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Events free survival
Endpoint domain: Mortality/survival
Primary endpoint: Successful implantation of VACStent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence Rate of Gastrointestinal Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ascites Volume (mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ratio of Phospho-AKT (p-AKT) to AKT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of tinnitus
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of functional CMV or EBV-protein-reactive blood leucocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Treatment Emergent Adverse Events assessed by hematology and clinical pathology blood tests
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment Emergent Adverse Events assessed by vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment Emergent Adverse Events assessed by ECG
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment Emergent Adverse Events assessed by dermal assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration Versus Time Curve of Ocrelizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Ocrelizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of CD 19+ B-cell Count in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Timed up and Go Test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in plasma glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CAR-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of diuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: c-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of the Antibody Response to Each of the Human Papillomavirus (HPV) Types Contained in V503
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With >=4-fold Increase in Antibody Titers to Neisseria Meningitidis Serogroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Achieve Acceptable Titers of Anti-Diphtheria and Anti-Tetanus Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in liver volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Active Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of hypertension/preeclampsia in pregnancy or postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetoplacental circulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in ESSDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School Retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Active Travel to School Based on Parental Report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in MVPA During the Times Reported by the Parent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in endothelium-dependent flow mediated vasodilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Device or procedure related serious adverse events rate
Endpoint domain: Adverse events/effects
Primary endpoint: Minimal residual disease (MRD) negativity rate in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scar evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in mental health status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Local reaction after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Systemic event after vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of intercostal drains requiring re-siting
Endpoint domain: Adverse events/effects
Primary endpoint: Colonic Transit, Geometric Center at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ascending Colon Emptying T1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fore-arm insulin uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of hospital readmitted patients
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Occurrence of PAH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anal sphincters injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in Part 1 Treatment Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in the Active Treatment Extension Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability and safety of the vaccine regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Full-dose Donor Chimerism (FDC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI analysis using semiquantitative whole organ scoring method (WORMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in blood hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Abnormal interpretation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Last Planned Glycosylated Haemoglobin (HbA1c) Prior to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Follow up outcomes after tracheostomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute graft versus host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of misclassification of ethnicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in functional mobility during walking
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Podocyturia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of pediatric chronically ill patients correctly vaccinated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of adult chronically ill patients correctly vaccinated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with a new pressure sore
Endpoint domain: Adverse events/effects
Primary endpoint: Patients' perspective of their physical and psychosocial rehabilitation needs
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patients' experiences of the physical and social impact of cancer
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Patients' met and un-met needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bailey-III test punctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival time without biochemical recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Amount of tissue repaired
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative CDVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero hours to last quantifiable time (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero hours to infinite (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative pain assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent risk of a fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Drug Cue Reactivity BOLD Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in best corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes